Popular Articles

Cancer Therapeutics, Inc.'s Partner NanoTherapies, Inc. Utilizes Revolutionary Solution For Disrupting And Treating Cancer
Cancer Therapeutics, Inc. (OTCBB: CTHP), an emerging biotechnology business incubator with a specific emphasis on disruptive cancer treatments and nanotechnology, announced its new partner, NanoTherapies, Inc., is utilizing calcium phosphate nanoparticles to detect and treat cancer. These particles are about 350 times smaller than a human cell while providing both a safe and effective way to transport drugs and imaging materials into diseased cells.

Cephalon Provides Clinical Update On Lestaurtinib In Relapsed Acute Myelogenous Leukemia
Cephalon, Inc. (Nasdaq: CEPH) announced results from a pivotal clinical trial of lestaurtinib (CEP-701) in patients with relapsed acute myelogenous leukemia (AML) expressing FLT3 activating mutations. The study was designed to show the benefit of lestaurtinib in this patient population when given in sequence with standard induction chemotherapy compared to those treated with standard induction chemotherapy alone. An analysis of the study showed that patients who were treated with lestaurtinib showed similar rates of complete response but no increased benefit in overall survival, compared to those who received induction chemotherapy alone.
News of the day
Developing World Health Care Solutions Help Some U.S. Programs
The Wall Street Journal examines how some U.S.-based health care programs are improving their treatment capabilities by learning from strategies used in developing countries. "When doctors running the AIDS clinic at the University of Alabama at Birmingham wanted to increase the number of patients who showed up for treatment, they turned to an unusual place for help: southern Africa," Wall Street Journal writes. By using an AIDS clinic in Zambia as a model, the Alabama clinic was able to decrease its no-show rate "from 31% in 2007 to 18% through June 2009."
Mental Health

Study Finds Reproductive Health Effects From Low Doses Of Bisphenol-A

New research from North Carolina State University and the National Institute of Environmental Health Sciences (NIEHS) shows significant reproductive health effects in rats that have been exposed to bisphenol-A (BPA) at levels equivalent to or below the dose that has been thought not to produce any adverse effects. BPA is a chemical found in baby bottles, water bottles, canned foods and an array of other consumer products. The potential health effects of BPA are currently the subjects of intense debate. The study found that female rats exposed to a BPA dose of 50 micrograms per kilogram of body weight (÷µg /kg) in their first four days of life experienced early onset of puberty. Female rats exposed to 50 milligrams per kilogram of body weight (mg/kg) during their first four days of life developed significant ovarian malformations and premature loss of their estrus cycle. "The 50 mg/kg level is important," says lead researcher Dr. Heather Patisaul, "because it is equivalent to the U.S. Environmental Protection Agency"s "Lowest Observable Adverse Effect Level" for BPA. So, by definition, we should not have seen significant effects at or below this level, but we did." Patisaul, an assistant professor of biology at NC State, explains that the 50 ÷µg /kg level is also significant because it is EPA"s listed reference dose for BPA - meaning it is the level of BPA that EPA says a person can be exposed to on a daily basis without expecting any adverse effects after a lifetime of exposure. Patisaul stresses that the research was done on rats, making it difficult to determine its applicability to humans, but notes that "this adds to a growing body of evidence that exposure to low doses of BPA during development can impact female reproductive health." The female rats in the study were exposed during the first four days of life because that is a sensitive developmental window for the rats, similar to a sensitive developmental stage that takes place for humans when they are still in the womb. While exposure to the lowest dose, 50 ÷µg /kg, resulted in early onset of puberty in the rats, exposure to higher dose had more complicated results. When exposed to the higher 50 mg/kg dose, the female rats developed cyst-like formations in their ovaries. The ovaries also developed fewer so-called "corpora lutea" structures than normal. Corpora lutea appear after ovulation and are essential to fertility because they produce a hormone called progesterone. If an ovary does not produce enough progesterone, it is impossible for a female to sustain a pregnancy. The lack of corpora lutea likely indicate that the female rats were no longer ovulating and would probably be infertile. Exposure to the higher 50 mg/kg dose also resulted in the female rats prematurely losing their estrous cycle. The researchers determined this by observing a lack of change in the skin cells of the female reproductive tract of the rats across the estrous cycle. These cellular changes indicate a normal estrus cycle. The study, "Neonatal bisphenol-A exposure alters rat reproductive development and ovarian morphology without impairing activation of gonadotropin releasing hormone neurons," was funded by NIEHS and published online June 17 by the journal Biology of Reproduction. The study was co-authored by Patisaul and Heather B. Adewale of NC State and Wendy N. Jefferson and Retha R. Newbold at NIEHS. Matt Shipman North Carolina State University


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):